VLS Shares Vita Life Sciences Limited
ASX · ASXLast in our picks 2026-10-23 — not in the current list; analysis below is from that screen
Healthcare-product portfolio expansion provides defensive growth and operating leverage.
Signal breakdown
- ▸Portfolio expansion and improving healthcare-sector momentum.
- ▸Above 50-day MA (+1.42%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (84.1% of range) — strength
Is VLS a buy right now?
Trend: VLS is trading above the 50-day average (+0.72%), RSI 47 — neutral momentum, with a 3-month return of +14.75%.
Valuation & quality: Vita Life Sciences Limited trades on a trailing P/E of 14.7, price-to-book 2.83; fundamentals show net margin 11.6%, return on equity 20.6%, revenue growth 6.1% year on year.
Income: trailing dividend yield 5.18%.
Our screen: BUY (score 3) — Healthcare-product portfolio expansion provides defensive growth and operating leverage.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -5.60% | +0.40% | -5.10% | +4.20% | -2.40% | +13.10% | -0.40% | +1.80% |
Fundamentals
Technical signals
About Vita Life Sciences Limited
Vita Life Sciences Limited, a healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. The company offers various minerals, herbs, and superfoods.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.